<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In contrast to adults, autologous stem cell transplantation (ASCT) as part of the salvage strategy after high-dose chemo/radiotherapy in human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus (HIV) related Non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) is not yet established for children </plain></SENT>
<SENT sid="1" pm="."><plain>We report on a 13-year patient with <z:e sem="disease" ids="C0520783" disease_type="Disease or Syndrome" abbrv="">congenital HIV infection</z:e> and refractory Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, who was successfully treated by high-dose therapy (HDT) including rituximab followed by ASCT </plain></SENT>
<SENT sid="2" pm="."><plain>After 26 months follow-up the patient remains in complete remission and his HIV parameters have normalized with continued highly active antiretroviral therapy (HAART) </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> may no longer exclude children from ASCT as part of salvage therapy </plain></SENT>
</text></document>